Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.

The DDR1 and DDR2 receptor tyrosine kinases are activated by extracellular collagen and have been implicated in a number of human diseases including cancer. We performed a fragment-based screen against DDR1 and identified fragments that bound either at the hinge or in the back pocket associated with the DFG-out conformation of the kinase. Modeling based on crystal structures of potent kinase inhibitors facilitated the "back-to-front" design of potent DDR1/2 inhibitors that incorporated one of the DFG-out fragments. Further optimization led to low nanomolar, orally bioavailable inhibitors that were selective for DDR1 and DDR2. The inhibitors were shown to potently inhibit DDR2 activity in cells but in contrast to unselective inhibitors such as dasatinib, they did not inhibit proliferation of mutant DDR2 lung SCC cell lines.

[1]  Kiki Chu,et al.  Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors , 2014, Journal of molecular biology.

[2]  Paul H. Huang,et al.  Discoidin Domain Receptor 2 Signaling Networks and Therapy in Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Xiaoyun Lu,et al.  Small molecule discoidin domain receptor kinase inhibitors and potential medical applications. , 2015, Journal of medicinal chemistry.

[4]  Bin Fang,et al.  Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. , 2014, Cancer research.

[5]  H. Nguyen,et al.  Identification of type II and III DDR2 inhibitors. , 2014, Journal of medicinal chemistry.

[6]  H. Oki,et al.  A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases. , 2012, ACS medicinal chemistry letters.

[7]  Mladen Vinković,et al.  Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. , 2009, Journal of medicinal chemistry.

[8]  Daniel Elbaum,et al.  Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. , 2007, Journal of medicinal chemistry.

[9]  M. Meyerson,et al.  Cancer Biology and Signal Transduction Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by Ddr2 Gatekeeper Mutation and Nf1 Loss , 2022 .

[10]  M. Meyerson,et al.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. , 2011, Cancer discovery.

[11]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[12]  Kevin W. Eliceiri,et al.  The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis , 2013, Nature Cell Biology.

[13]  F. Sommen,et al.  Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase. , 2015, ACS medicinal chemistry letters.

[14]  Christopher W Murray,et al.  Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. , 2005, Journal of medicinal chemistry.

[15]  V. Fokin,et al.  Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach. , 2013, Bioorganic & medicinal chemistry letters.

[16]  G. Yancopoulos,et al.  An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. , 1997, Molecular cell.

[17]  P. Bamborough,et al.  Kinase array design, back to front: biaryl amides. , 2008, Bioorganic & medicinal chemistry letters.

[18]  Ping Chen,et al.  2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase in , 2006, Journal of medicinal chemistry.

[19]  C. Ford,et al.  Sensing extracellular matrix: an update on discoidin domain receptor function. , 2006, Cellular signalling.

[20]  J. Madwed,et al.  Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. , 2002, Journal of medicinal chemistry.

[21]  Kristen M. Naegle,et al.  Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants , 2013, The Biochemical journal.

[22]  B. Leitinger,et al.  Transmembrane collagen receptors. , 2011, Annual review of cell and developmental biology.

[23]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[24]  Paul Bamborough,et al.  Selectivity of kinase inhibitor fragments. , 2011, Journal of medicinal chemistry.

[25]  Marcel L Verdonk,et al.  Identification of inhibitors of protein kinase B using fragment-based lead discovery. , 2007, Journal of medicinal chemistry.

[26]  C. Murray,et al.  Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models , 2011, Molecular Cancer Therapeutics.

[27]  Paul G Wyatt,et al.  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.

[28]  Ke Ding,et al.  Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. , 2013, Journal of medicinal chemistry.

[29]  Celina G. Kleer,et al.  Discoidin domain receptor tyrosine kinases: new players in cancer progression , 2012, Cancer and Metastasis Reviews.

[30]  G. Bemis,et al.  BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease. , 2004, Journal of medicinal chemistry.

[31]  Sam W. Lee,et al.  Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor , 2013, ACS chemical biology.